Resmed (RSMDF) Gross Profit (2009 - 2026)

Resmed has reported Gross Profit for 18 years, with the latest figure at $891.0 million in Q1 2026.

• For the quarter ending Q1 2026, Gross Profit rose 16.25% year-over-year to $891.0 million; the trailing twelve-month figure through Mar 2026 stood at $3.4 billion (up 15.6% YoY), and the FY2025 full-year result was $3.1 billion, up 15.05% from the prior year.
• Gross Profit for Q1 2026 stood at $891.0 million, up from $878.7 million in the prior quarter.
• The five-year high for Gross Profit was $891.0 million in Q1 2026, with the low at $491.2 million in Q1 2022.
• Historically, Gross Profit has averaged $686.5 million across 5 years, with a median of $692.8 million in 2024.
• Annual changes were most pronounced in 2022 — Gross Profit rose 6.48% — and 2023, when it climbed 25.76%.
• Resmed's Gross Profit stood at $579.7 million in 2022, then climbed by 11.6% to $646.9 million in 2023, then gained by 16.13% to $751.3 million in 2024, then grew by 16.96% to $878.7 million in 2025, then gained by 1.39% to $891.0 million in 2026.
• The last three Gross Profit figures came in at $891.0 million (Q1 2026), $878.7 million (Q4 2025), and $820.8 million (Q3 2025), per Business Quant data.